Dupilumab for asthma remission
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether dupilumab, a medicine that helps reduce airway inflammation, can help people with asthma achieve remission. You may be eligible if you have asthma with high markers of inflammation and have had asthma attacks despite using your regular inhaler.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have had asthma for at least 6 months.
- Your asthma tests show you have inflammation (elevated eosinophils and FeNO) at screening.
- You have had at least one asthma attack in the last 2 years that required steroid pills or an emergency visit.
- You have been using a medium or high dose inhaled steroid regularly for at least 3 months.
- You are not a current smoker and have not smoked in the last 6 months.
- You are not already eligible for dupilumab for other conditions like eczema or nasal polyps.
- You can attend study visits and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
Hear when a new Asthma Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.